Kiniksa Pharmaceuticals Azioni (NASDAQ: KNSA)

Ultime notizie per Kiniksa Pharmaceuticals (NASDAQ:KNSA) Azioni

Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals International PLC

Ford Motor Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) is determined to move forward with the construction of its $3 billion&nbsp;battery plant in Michigan, even&nbsp;if the project loses its eligibility for federal tax incentives.
What Happened:&nbsp;Ford&#8217;s decision to continue with the project comes amid potential policy changes by the U.S. government that could render the plant ineligible for federal tax credits, <a href="https://www.nytimes.com/2025/06/23/business/ford-battery-factory-electric-vehicles.html">reported</a>&nbsp;The New York Times&nbsp;on Monday.&nbsp;The plant, located in Marshall, Michigan, is expected to utilize battery and manufacturing technology licensed from the Chinese company&nbsp;Contemporary Amperex Technology Ltd.&nbsp;(CATL).
The Inflation Reduction Act, a key energy and climate change legislation passed under the administration of former President Joe Biden, was anticipated to provide federal tax credits to offset a portion of the plant&#8217;s costs. However, current Republican efforts in Congress may result in the exclusion of battery plants using Chinese technology or materials from federal support. 
Despite these potential changes, Ford is committed to the project.&nbsp;Lisa Drake, Ford&#8217;s&nbsp;vice president for technology platform&nbsp;programs and E.V. systems, stated, &#8220;We&nbsp;don't want to back off&nbsp;on this facility. When&nbsp;we invest, we stick behind&nbsp;our investments. Ford is a&nbsp;company that will weather the&nbsp;storm until we get there.&#8221;
The plant, scheduled to commence production next year, is projected to create 1,700 jobs and produce batteries using lithium, iron, and phosphate. 
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/large-cap/25/06/46044073/small-investment-bank-tied-to-trumps-sons-facilitated-120-million-trading-windfall" target="_blank" rel="noreferrer noopener">Small Investment Bank Tied to Trump's Sons Facilitated $120 Million Trading Windfall &#8211; Benzinga</a>
Why It Matters: The potential loss of tax incentives for Ford&#8217;s battery plant comes amid President Donald Trump&#8216;s crackdown on all-electric mobility in the country. 
Senate Republicans have proposed a bill to end the $7500 EV credit<a href="https://www.benzinga.com/markets/tech/25/06/45965638/amid-trumps-anti-ev-push-senate-republicans-propose-tax-bill-to-axe-7500-ev-credit"> currently available </a>on EV purchases within 180 days after the proposal is signed into law. 
Earlier in February, automakers like General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Ford had appealed to lawmakers to gradually phase out electric-vehicle (EV) tax credits over several years, rather than <a href="https://www.benzinga.com/markets/25/02/43648415/tesla-rivals-call-for-gradual-elimination-of-ev-tax-credits-many-of-those-jobs-will-be-at-risk">abruptly ending</a> them.
On a year-to-date basis, shares of Ford surged 11.4% as per<a href="https://www.benzinga.com/pro/"> Benzinga Pro</a>.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://www.benzinga.com/markets/tech/25/06/46068633/ford-recalls-aviator-suvs-as-adhesive-issue-adds-to-automakers-mounting-recall-woes">Ford Recalls Aviator SUVs As Adhesive Issue Adds To Automaker&#8217;s Mounting Recall Woes</a> </li>
<li>Image via Shutterstock</li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

News

Ford To Proceed With $3 Billion Battery Plant Despite Potential Tax Incentive Loss Under Trump's Budget Plan: 'We Stick Behind Our Investments'

Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) is looking for Q3 Adj EPS of $1.30 vs $1.32 analyst estimate..

Guidance

Carnival Sees Q3 Adj EPS $1.30 vs $1.32 Est

WF Holding Plans To Make Investments In China To Expand Business Scope And Promote Bilateral Economic Cooperation And Technological Exchanges

Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) raises FY2025 Adj EPS guidance from $1.83 to $1.97 vs $1.89 analyst estimate..

Carnival Raises FY2025 Adj EPS Guidance from $1.83 to $1.97 vs $1.89 Est

Stephens &amp; Co. analyst Sudan Loganathan upgrades Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from Equal-Weight to Overweight and raises the price target from $29 to $60.

Upgrades

Price Target

Analyst Ratings

EXEL

Stephens & Co. Upgrades Exelixis to Overweight, Raises Price Target to $60

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Live On CNBC, Visa CEO Ryan McInerney Says "We've Been Embracing Stablecoins"

-AI Audience + AI Creative AI agent solution – integrates language models and generative technologies for marketing process automation by utilizing five intelligent models &nbsp;
-Proprietary AI-powered content management system supports media brands in improving editorial efficiency and content exposure &nbsp;
-AI-based display ad optimization drives revenue growth in display ad segment of Media &amp; Branded Content business unit &nbsp;
-AI-driven cost reduction initiatives drove 5% reduction in group-level human capital intensity in May vs. same month last year
NEW YORK and TOKYO, June 24, 2025 /PRNewswire/ -- TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) (the "Company"), a Tokyo-based next-generation digital media and data group in Asia, today announced a collection of new AI-based initiatives focused on boosting productivity at the Company, including the launch of both its AI Agent product "AI Audience + AI Creative", AI-driven display ad revenue optimization and AI-driven cost reduction initiatives that have lowered group-level human capital intensity by 5%.

TNMG

TNL Mediagene Launches AI Agent Solution "AI Audience + AI Creative", Ad Optimization, And Cost-Cutting Initiatives, Reducing Human Capital Intensity By 5% In May Vs. Same Month Last Year

Carnival Corporation Sees Q3 Net Yields Up Approximately 3.5% Compared To 2024 Levels, Which Were Up Almost 9%

Barclays analyst Luke Sergott initiates coverage on West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Equal-Weight rating and announces Price Target of $245.

Initiation

Barclays Initiates Coverage On West Pharmaceutical Servs with Equal-Weight Rating, Announces Price Target of $245

Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Outperform and maintains $715 price target.

Reiteration

ARGX

Wedbush Reiterates Outperform on argenx, Maintains $715 Price Target

Morgan Stanley analyst Toni Kaplan maintains FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) with a Underweight and raises the price target from $390 to $393.

Morgan Stanley Maintains Underweight on FactSet Research Systems, Raises Price Target to $393

For the full year 2025, the company expects:
<ul>
<li>Net yields (in constant currency) approximately 5.0 percent higher than strong 2024 levels, which were up 11 percent and 0.3 percentage points better than March guidance.</li>
<li>Adjusted cruise costs excluding fuel per ALBD (in constant currency) up approximately 3.6 percent compared to 2024, better than March guidance.</li>
<li>Adjusted net income up over 40 percent compared to 2024 and better than March guidance by $200 million.</li>
<li>Adjusted EBITDA of approximately $6.9 billion, up over 10 percent compared to 2024 and better than March guidance.</li>
</ul>

Carnival Corporation Sees FY25 Net Yields Approximately 5% Higher Than 2024 Levels, Which Were Up 11%

- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) vs GnP alone
- Patients with liver metastases experienced a 2.5x improvement in 1-year OS with a 38% reduction in risk of death when treated with elraglusib plus GnP
CHICAGO and FORT WORTH, Texas, June 24, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today highlighted results from a pre-specified subgroup analysis of its Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic adenocarcinoma (mPDAC).
Patients treated for at least one complete cycle (4 weeks) of therapy achieved a median overall survival (mOS) of 12.5 months in the elragusib/GnP arm, compared to 8.5 months in the control arm. The analysis showed a 43% reduction in the risk of death relative to control, highlighting the significant potential impact of early disease control by elraglusib. Improved outcomes were reported in the combination versus control arms, respectively: disease control rate (DCR): 53.4% vs 44.8%, overall response rate (ORR): 37.9% vs 29.3%, and median progression-free survival (PFS): 6.9 vs 5.6 months.

ACTU

Actuate Therapeutics Highlights Results From Pre-Specified Subgroup Analysis Of Phase 2 Trial Of Elraglusib In Combination With GnP In First-Line Metastatic Pancreatic Adenocarcinoma

Study evaluates novel small molecule TNF-alpha inhibitor as potential alternative to biologic treatments
TNF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has formed a philanthropic collaboration with the DADA2 Foundation, a nonprofit organization seeking innovative ways to accelerate research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). Together, the parties are expected to initiate a Compassionate Use (Expanded Access) study evaluating TNF's lead candidate isomyosamine as a potential treatment.
The DADA2 Foundation describes DADA2 as a rare, monogenic recessively inherited autoinflammatory disease characterized by systemic inflammation, vasculitis, early-onset stroke, immunodeficiency, and bone marrow failure. The condition can lead to recurring childhood strokes at a young age and a high risk of premature death before adulthood. Early diagnosis is critical to minimize systemic organ damage.
TNF President and Chief Medical Officer, Mitchell Glass, M.D. commented, "The body of evidence surrounding DADA2 has shown that TNF inhibition is a most effective treatment for the hyperinflammatory and vasculitic aspects of this disease—a potentially fatal condition that primarily affects children. Compared with standard-of-care biological treatments, our TNF-alpha inhibitor, isomyosamine, is an orally administered small molecule with comparable potency, easier titration to the intended effect and, most importantly, anti-inflammatory action with minimal or no immunosuppression. We believe it could be a superior alternative for treating this devastating disease."
DADA2 Foundation Founder and President, Chip Chambers, M.D. commented, "Biological TNF inhibitors have shown to be the only safe and effective treatment for DADA2 patients with autoinflammatory/vasculitic forms of DADA2, but have many limitations including route of administration, cost, and the potential to lose efficacy over time. We are excited to explore isomyosamine as a potential new treatment to improve the lives of DADA2 patients and their families."
Approximately 25% of DADA2 patients are diagnosed before one year of age and 77% by 10 years of age. Patients who have bone marrow failure tend to present during early infancy, whereas delayed presentation is common in patients with vasculitis affecting medium- and small-sized vessels and systemic inflammation. There are more than 600 DADA2 patients today, but research suggests that 35,000 patients could be affected and undiagnosed globally.1

Biotech

General

TNFA

TNF Pharmaceuticals And DADA2 Foundation Launch Compassionate Use Study Of Oral TNF-Alpha Inhibitor Isomyosamine For Rare Pediatric Inflammatory Disease

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) with a Outperform and lowers the price target from $17 to $15.

Larimar Therapeutics, Inc. - Common Stock

LRMR

Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $15

Company also announces certain corporate actions
ROUND ROCK, TX / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 24, 2025 / AYRO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>) ("AYRO" or the "Company"), today announces that it is exploring a range of strategic alternatives to enhance stockholder value, including digital asset initiatives, with a focus on the underlying technology of crypto-based stablecoins, and operational initiatives to grow its core business.
As part of this process, the Company is actively exploring new market opportunities that leverage its existing assets and balance sheet.
AYRO currently maintains a strong cash position of approximately $15.4 million, as of March 31, 2025, enabling significant flexibility to pursue strategic paths and support external opportunities.
"We continue to actively explore all strategic avenues to create value for our stockholders," said Josh Silverman, Executive Chairman of AYRO. "We believe our solid balance sheet enables us to pursue growth opportunities in emerging digital markets with a specific interest in technologies underlying stablecoins.
Reverse Stock Split
Additionally, the Company today announces that it intends to effect a reverse stock split of its common stock, par value $0.0001 per share (the "common stock") at a ratio of 1 post-split share for every 16 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Wednesday, June 25, 2025. The Company's common stock will continue to be traded on the Nasdaq Capital Market under the symbol AYRO and will begin trading on a split-adjusted basis when the market opens on Thursday, June 26, 2025. The new CUSIP number for the common stock following the reverse stock split is 054748306.
At the 2025 annual meeting of stockholders held on May 19, 2025, the Company's stockholders granted the Company's Board of Directors the discretion to effect a reverse stock split of the Company's common stock through an amendment to its Amended and Restated Certificate of Incorporation, as amended, at a ratio of not less than 1-for-2 and not more than 1-for-100, with such ratio to be determined by the Company's Board of Directors.
At the effective time of the reverse stock split, every sixteen (16) shares of the Company's issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-16 reverse stock split. It is not necessary for stockholders holding shares of the Company's common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.

Stock Split

AYRO

AYRO Explores Strategic Alternatives Including Stablecoins; Announces 1-For-16 Reverse Stock Split, Will Begin Trading On A Split-Adjusted Basis When The Market Opens On Thursday, June 26, 2025

Morgan Stanley analyst Bob Huang maintains Voya Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>) with a Overweight and raises the price target from $86 to $88.

VOYA

Morgan Stanley Maintains Overweight on Voya Financial, Raises Price Target to $88

SVCO

Silvaco Group Announces Strategic R&D Collaboration With Fraunhofer Institute For Silicon Technology To Accelerate Development Of Next-Gen GaN Devices Using Silvaco's Power Devices Solution To Perform DTCO

Uber Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) shares are moving higher Tuesday. The company announced that it began offering autonomous ride options with <a href="https://www.benzinga.com/markets/tech/25/06/46051889/teslas-4-20-robotaxi-disruption-waymo-should-be-worried">Waymo in Atlanta</a>.
What Happened: Uber on Tuesday said users in Atlanta can now be paired with a Waymo autonomous vehicle exclusively on the Uber app. 
Uber said riders will be able to travel across a 65 square mile area of Atlanta at launch, with plans to expand that range in the future. Riders in Atlanta may now be matched with a Waymo fully autonomous Jaguar I-PACE vehicle. Upon arrival, riders can unlock the doors and start the trip using the Uber app. 
Uber and Waymo <a href="https://www.benzinga.com/markets/equities/24/09/40855784/uber-stock-spikes-as-ceo-praises-waymos-fully-autonomous-trips">announced</a> an expanded partnership in September 2024 to bring autonomous ride options to Austin and Atlanta through the Uber platform. The Atlanta launch comes after the companies launched autonomous ride-hailing in Austin in March. 
Competition in the autonomous space is starting to heat up with Tesla&#8217;s official robotaxi <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46058796/tesla-stock-is-surging-today-whats-driving-the-momentum">launch</a> taking place over the weekend. Tesla officially launched robotaxi rides on Sunday through a &#8220;successful&#8221; invitation-only event, CEO Elon Musk <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46058796/tesla-stock-is-surging-today-whats-driving-the-momentum">said</a> on X.
Riders were charged a flat fee of $4.20 per ride, but it&#8217;s not clear what the pricing strategy will look like moving forward. Uber on Tuesday said its autonomous rides will be offered at no additional cost in Atlanta. 
&#8220;In&nbsp;<a href="https://investor.uber.com/news-events/news/press-release-details/2024/Uber-and-Waymo-Expand-Partnership-to-Bring-Autonomous-Ride-Hailing-to-Austin-and-Atlanta/default.aspx">Austin</a>, where Waymo rides are also exclusively available on Uber, there are now 100 Waymo vehicles on the platform, and that number is growing as the fleet scales across both Austin and Atlanta,&#8221; Uber said on Tuesday. 
UBER Price Action: <a href="http://benzinga.com/quote/uber">Uber shares</a> were up 3.12% at $87.90 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46069883/teslas-china-sales-slip-over-10-in-mid-june-after-strong-may-surge">Tesla&#8217;s China Sales Slip Over 10% in Mid-June After Strong May Surge</a></li>
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45967745/honeywell-near-earth-autonomy-test-pilot-free-helicopter-for-faster-safer-marine-supply">Honeywell, Near Earth Autonomy Test Pilot-Free Helicopter For Faster, Safer Marine Supply</a></li>
</ul>
Photo: Shutterstock.

Movers

UBER

Uber Stock Is Moving Higher Tuesday: What's Driving The Action?

Barclays analyst Luke Sergott initiates coverage on Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Overweight rating and announces Price Target of $150.

RGEN

Barclays Initiates Coverage On Repligen with Overweight Rating, Announces Price Target of $150

Press Releases

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

Earnings

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

Health Care

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

Comments

Kiniksa Pharmaceuticals

Notizie

Ultime notizie per Kiniksa Pharmaceuticals (NASDAQ:KNSA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO